welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
- Therapeutic Approaches for Patients with Coexisting Familial Adenomatous Polyposis and Colorectal CancerColorectal cancer is a major cause of de...
- Selective COX-2 Inhibition Affects Fatty Acids, but not COX mRNA Expression in Patients with FAPFamilial adenomatous polyposis (FAP) pro...
- Bon Voyage: Traveling with a J-Pouch Part 1https://www.youtube.com/watch?v=NlhsEEuo...
- Total Proctocolectomy, Ileal Pouch Anal Anastomosis (J-Pouch, S-Pouch, W-Pouch)http://my.clevelandclinic.org/ccf/media/...
- Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulin...Cancer Prevention Pharmaceuticals, Inc.,...
- The Effects of Sulindac on the Pathology of Colorectal Remnant Polyps of Familial Adenomatous Polyposis (FAP) Patien...OBJECTIVE : To evaluate the long-term ef...
English
Portuguese